Quick Answer
Lantern Pharma Inc. reported Earnings Per Share Diluted of $1.57 (loss) per share for the year ending 2025.
- Lantern Pharma Inc. showed an increase of +18.7% in Earnings Per Share Diluted from 2024 to 2025.
- This data is from Lantern Pharma Inc.'s annual report (Form 10-K), filed with the SEC on March 30, 2026.
- XBRL data for this metric is available from 2022 to 2025 (4 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2022: $0.41 (loss) per share | Q3 2022: $0.21 (loss) per share | Q1 2023: $0.36 (loss) per share | Q2 2023: $0.44 (loss) per share | Q3 2023: $0.29 (loss) per share | Q1 2024: $0.51 (loss) per share | Q2 2024: $0.46 (loss) per share | Q3 2024: $0.42 (loss) per share | Q1 2025: $0.42 (loss) per share | Q2 2025: $0.40 (loss) per share | Q3 2025: $0.39 (loss) per share.
- Over the full 4 years of available data (2022 to 2025), Lantern Pharma Inc.'s Earnings Per Share Diluted has declined by 19.8%.
- Historical annual values: Fiscal year 2025: $1.57 (loss) per share | Fiscal year 2024: $1.93 (loss) per share | Fiscal year 2023: $1.47 (loss) per share | Fiscal year 2022: $1.31 (loss) per share.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: